Observational study on immune adsorption (IA) in patients with GPCR autoantibody-positive post-Covid/post-vac syndrome (IA-Surv)

Observational study on immune adsorption (IA) in patients with GPCR autoantibody-positive post-Covid/post-vac syndrome (IA-Surv) - IA-Surv

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033897

Enrollment

Registered

2025-01-27

Start date

2025-01-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U09.9

Interventions

Group 1: Observational study of the clinical course of 5 immunoadsorption therapies for post-Covid/post-vaccination syndrome. SF36, Chalder Bell Score, Canadian criteria (for ME/CFS), PEM questionnair

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: - Patients (female, male, diverse) aged 18 to 75 years who are legally competent and able to give consent, with post-Covid/post-Vac syndrome at least six months after a SARS-CoV-2 infection/vaccination, are included in the study - Proof of Covid infection at the start of the disease (post-Covid) or temporal connection to SARS-CoV-2 vaccination (post-Vac) - GPCR autoantibody positive - Clinical indication for immunoadsorption is present - Signed declaration of consent - Health insurance

Exclusion criteria

Exclusion criteria: - Lack of informed consent - Spicopathy: detection of spike proteins in plasma/serum, immune cells, - No sufficient peripheral veins for immunoadsorption therapy - Pregnancy - Serious illnesses other than the diagnosis of post-Covid/post-vac syndrome, severe heart failure (NYHA = III), renal failure, liver failure, acute infections (Covid, HIV, hepatitis, etc.). - Insufficient knowledge of the German language

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is to demonstrate an improvement in symptoms six weeks after the last immunoadsorption apheresis using the SF-36 questionnaire (physical functioning (PF)).	—

Secondary

Measure	Time frame
• Improvement of the Canadian criteria for ME/CFS, the stress intolerance (PEM) criteria, Chalder Fatigue Scale, Bell-Score and the values in the Covid health status, PHQ-D (short form) • Decline in agonistic adrenergic autoantibodies GPCR autoantibodies (in the bioassay; E.R.D.E. laboratory), • Monitoring the tolerability of immunoadsorption	—

Countries

Germany

Contacts

Public ContactHarald Matthes

Universitätsmedizin Charité

harald.matthes@charite.de+4930365017610

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026